CCND1 and papillary adenocarcinoma: Patients with durable RECIST SD included those with HNSCC with ARID2 frameshift (99 weeks), HNSCC with no sequencing available (48 weeks), HNSCC with CCND1 amplification (49 weeks), and digital papillary adenocarcinoma with TP53 mutation (51 weeks).